<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>Journal of Experimental &amp; Clinical Cancer Research - Latest articles</title>
		<link>http://www.jeccr.com</link>
		<description>The latest articles from Journal of Experimental &amp; Clinical Cancer Research (ISSN 1756-9966) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.jeccr.com/content/27/1/16"/>			    
            
				    <rdf:li rdf:resource="http://www.jeccr.com/content/27/1/15"/>			    
            
				    <rdf:li rdf:resource="http://www.jeccr.com/content/27/1/14"/>			    
            
				    <rdf:li rdf:resource="http://www.jeccr.com/content/27/1/13"/>			    
            
				    <rdf:li rdf:resource="http://www.jeccr.com/content/27/1/11"/>			    
            
				    <rdf:li rdf:resource="http://www.jeccr.com/content/27/1/10"/>			    
            
				    <rdf:li rdf:resource="http://www.jeccr.com/content/27/1/9"/>			    
            
				    <rdf:li rdf:resource="http://www.jeccr.com/content/27/1/8"/>			    
            
				    <rdf:li rdf:resource="http://www.jeccr.com/content/27/1/7"/>			    
            
				    <rdf:li rdf:resource="http://www.jeccr.com/content/27/1/6"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.jeccr.com/content/27/1/16">
            
            <title>Monitoring of people and workers exposure to the  electric, magnetic and electromagnetic fields  in an Italian national cancer Institute 

</title>
			<description>Background:
The paper reports the electric, magnetic and electromagnetic fields (emf) measurements carried out in the Regina Elena National Cancer Institute (NCI). Several devices, used in diagnostics and in medical cures, can represent sources of emf for the workers and for the public subjected to the treatments. The aim is to evaluate their exposition, in order to assess the compliance with the law.
Methods:
The investigations have been carried out in the departments of: intensive care, physiotherapy, MR presstherapy and in the surgical rooms. The measurements have been performed using broad band probes in the frequency ranges 5 Hz30 kHz and 100 kHz-3 GHz.  
Results:
The variability of the magnetic induction (B(uT)) levels is between 0,05 uT and 80 uT. The statistical distribution shows that most of the measurements are in the range 0,05&lt;B[less than or equal to]0,5 uT and the 89% of the B(uT) levels are within the 3 uT.
Conclusions:
The measurement of the emf levels in the NCI is recommended because of the presence of the oncological patients; their long stay near the equipments and their day-long exposure represent additional risk factors for which a prudent avoidance strategy have to de adopted. </description>
			<link>http://www.jeccr.com/content/27/1/16</link>
			
			 	<dc:creator>Anna Maria Di Nallo, Lidia Strigari, Claudia Giliberti, Angelico Bedini, Raffaele Palomba and Marcello Benassi</dc:creator>
			
			<dc:source>Journal of Experimental &amp; Clinical Cancer Research 2008, 27:16</dc:source>
			<dc:date>2008-07-03</dc:date>
			<dc:identifier>doi:10.1186/1756-9966-27-16</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Experimental &amp; Clinical Cancer Research</prism:publicationName>
					
			
							
					<prism:issn>1756-9966</prism:issn>
					
			
							
					<prism:volume>27</prism:volume>
					
			
							
					<prism:startingPage>16</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-03</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jeccr.com/content/27/1/15">
            
            <title>CSE1L/CAS, the cellular apoptosis susceptibility protein, enhances invasion and metastasis but not proliferation of cancer cells</title>
			<description>Background:
The cellular apoptosis susceptibility (CAS) protein is regarded as a proliferation-associated protein that associates with tumour proliferation as it associates with microtubule and functions in the mitotic spindle checkpoint. However, there is no any actual experimental study showing CAS (or CSE1 and CSE1L) can increase the proliferation of cancer cells. Previous pathological study has reported that CAS was strongly positive stained in all of the metastasis melanoma that be examined. Thus, CAS may regulate the invasion and metastasis of cancers. CAS is highly expressed in cancers; if CAS is associated with cancer proliferation, then increased CAS expression should be able to increase the proliferation of cancer cells. We studied whether increased CAS expression can increase cancer cell proliferation and whether CAS regulates the invasion of cancer cells.
Methods:
We enhanced or reduced CAS expression by transfecting CAS or anti-CAS expression vectors into human MCF-7 breast cancer cells. The proliferations of cells were determined by trypan blue exclusion assay and flow cytometry analysis. Invasion of cancer cells were determined by matrigel-based invasion assay.
Results:
Our studies showed that increased CAS expression was unable to enhance cancer cell proliferation. Immunofluorescence showed CAS was distributed in cytoplasm areas near cell membrane and cell protrusions. CAS was localized in cytoplasmic vesicle and immunogold electronmicroscopy showed CAS was located in vesicle membrane. CAS overexpression enhanced matrix metalloproteinase-2 (MMP-2) secretion and cancer cell invasion. Animal experiments showed CAS reduction inhibited the metastasis of B16-F10 melanoma cells by 56% in C57BL/6 mice.
Conclusions:
Our results indicate that CAS increases the invasion but not the proliferation of cancer cells. Thus, CAS plus ECM-degradation proteinases may be used as the markers for predicting the advance of tumour metastasis.</description>
			<link>http://www.jeccr.com/content/27/1/15</link>
			
			 	<dc:creator>Ching FONG Liao, Shue FEN Luo, Li TZU Li, Chuang YU Lin, Ying CHUN Chen and Ming CHUNG Jiang</dc:creator>
			
			<dc:source>Journal of Experimental &amp; Clinical Cancer Research 2008, 27:15</dc:source>
			<dc:date>2008-07-03</dc:date>
			<dc:identifier>doi:10.1186/1756-9966-27-15</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Experimental &amp; Clinical Cancer Research</prism:publicationName>
					
			
							
					<prism:issn>1756-9966</prism:issn>
					
			
							
					<prism:volume>27</prism:volume>
					
			
							
					<prism:startingPage>15</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-03</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jeccr.com/content/27/1/14">
            
            <title>Comparison of methods to determine accurate dose calibrator activity measurements </title>
			<description>Background:
In nuclear medicine, liquid radiopharmaceuticals for diagnostic or therapeutic purposes are administered to patients by using various types of syringes with different volumes. The activity of each dose must be carefully measured and documented prior to administration using an activity calibrator.  
Methods:
Calibrator response is a function of the measurement geometry and, in particular, it depends on the syringe type and filling volume. To minimize the uncertainty associated with the measured activity of the syringe, it is necessary to calculate a calibration curve for each syringe type and filling volume. This curve can be obtained by fitting  experimentally determined volume correction factors. 
Results:
A theoretical evaluation of volume correction factors for syringes is reported for three different experimental methods.  The aim is to determine the most accurate experimental method among those considered, by examining the expression of uncertainty for the correction factor. This theoretical analysis was then tested experimentally. 
Conclusions:
The agreement between the experimental data obtained in the constant activity method and gravimetric method at constant specific activity and the small associated uncertainties show the accuracy of these two procedures; while the volumetric method at constant specific activity could lead to a wrong evaluation of the correction factors.</description>
			<link>http://www.jeccr.com/content/27/1/14</link>
			
			 	<dc:creator>Lidia Strigari, Marcello Benassi, Pierino De Felice, Marco D'Andrea, Aldo Fazio, Sandro Nocentini, Annelisa d'Angelo and Alessia Ceccatelli</dc:creator>
			
			<dc:source>Journal of Experimental &amp; Clinical Cancer Research 2008, 27:14</dc:source>
			<dc:date>2008-07-01</dc:date>
			<dc:identifier>doi:10.1186/1756-9966-27-14</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Experimental &amp; Clinical Cancer Research</prism:publicationName>
					
			
							
					<prism:issn>1756-9966</prism:issn>
					
			
							
					<prism:volume>27</prism:volume>
					
			
							
					<prism:startingPage>14</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-01</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jeccr.com/content/27/1/13">
            
            <title>Implication of heme oxygenase-1 in the sensitivity of nasopharyngeal carcinomas to radiotherapy</title>
			<description>High expression of the inducible isoform of heme oxygenase (HO-1) is well known in various solid tumors in humans and experimental animal models.  To investigate the relationship between HO-1 and nasopharyngeal carcinoma, especially its involvement in the response of nasopharyngeal carcinoma to radiotherapy, thirty-two nasopharyngeal carcinomas were semi-quantitatively analyzed by RT-PCR, and the expression of HO-1 was correlated with the consequence after novel radiotherapy, which was evaluated by the reduction of tumor size.  Among 32 nasopharyngeal carcinomas, HO-1 expression was found in19 samples (59.4%), in which 9 patients (47.4%) showed no response to radiotherapy.  Interestingly, in 13 nasopharyngeal carcinoma patients with negative expression of HO-1, radiotherapy exhibited to be effective (9 patients, 69.2%) or responsive (3 patients, 23.1%).  In this study, we first demonstrated the expression of HO-1 in nasopharyngeal carcinomas, and more important, these findings strongly suggest the potential of HO-1as a useful index in identifying patients with well response to radiotherapy, further these data indicate a new therapeutic for nasopharyngeal carcinoma by inhibiting HO-1 activity, which warrants further investigation.</description>
			<link>http://www.jeccr.com/content/27/1/13</link>
			
			 	<dc:creator>Lei Shi and Jun Fang</dc:creator>
			
			<dc:source>Journal of Experimental &amp; Clinical Cancer Research 2008, 27:13</dc:source>
			<dc:date>2008-06-26</dc:date>
			<dc:identifier>doi:10.1186/1756-9966-27-13</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Experimental &amp; Clinical Cancer Research</prism:publicationName>
					
			
							
					<prism:issn>1756-9966</prism:issn>
					
			
							
					<prism:volume>27</prism:volume>
					
			
							
					<prism:startingPage>13</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-26</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jeccr.com/content/27/1/11">
            
            <title>Effect of pathologic fractures on survival in multiple myeloma patients: a case control study</title>
			<description>Background:
Multiple Myeloma (MM) is a B cell neoplasm characterized by the clonal proliferation of plasma cells. Skeletal complications are found in up to 80% of myeloma patients at presentation and are major cause of morbidity.
Methods:
49 patients were enrolled with MM admitted to Black Sea Technical University Hospital between 2002&#8211;2005. Pathologic fractures (PFs) were determined and the patients with or without PF were followed up minumum 3 years for survival analysis.
Results:
PF was observed in 24 patients (49%) and not observed in 25 patients (51%). The risk of death was increased in the patients with PF compared with patients who had no fractures. While overall survival was 17.6 months in the patients with PFs, it was 57.3 months in the patients with no PFs.
Conclusion:
These findings suggest that PFs may induce reduced survival and increased mortality in the MM patients, however, larger sample size is essential to draw clearer conclusions added to these data.</description>
			<link>http://www.jeccr.com/content/27/1/11</link>
			
			 	<dc:creator>Mehmet Sonmez, Tulin Akagun, Murat Topbas, Umit Cobanoglu, Bircan Sonmez, Mustafa Yilmaz, Ercument Ovali and Serdar Bedii Omay</dc:creator>
			
			<dc:source>Journal of Experimental &amp; Clinical Cancer Research 2008, 27:11</dc:source>
			<dc:date>2008-06-10</dc:date>
			<dc:identifier>doi:10.1186/1756-9966-27-11</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Experimental &amp; Clinical Cancer Research</prism:publicationName>
					
			
							
					<prism:issn>1756-9966</prism:issn>
					
			
							
					<prism:volume>27</prism:volume>
					
			
							
					<prism:startingPage>11</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-10</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jeccr.com/content/27/1/10">
            
            <title>Possible additional value of 18FDG-PET in managing pancreas intraductal papillary mucinous neoplasms: Preliminary results</title>
			<description>Although some clinical and radiological features may predict malignancy presence in intraductal papillary mucinous pancreas neoplasms, preoperative diagnosis remains difficult. In this study we present 7 patients with Intraductal Papillary Mucinous Neoplasm (IPMN) studied both with 18FDG-PET and magnetic resonance cholangiopancreatography (MRCP). A focal hypermetabolism was documented in 2 patients (the standardized uptake value in the neoplastic foci was 6.7 and 9), while absence of FDG uptake in the neoplasm area was recorded in the remaining 5 cases. Mean follow-up was 27 months (range 21&#8211;34). The final judgement was benign IPMN in 5 cases and malignant IPMN in 2. PET scan always correctly predicted the presence or absence of malignancy, while MRCP failed to detect malignancy in 3/7 cases. In conclusion, this preliminary experience suggests that 18FDG-PET may prove useful for malignancy detection in IPMN, improving differential diagnosis with benign intraductal papillary growth by functional data.</description>
			<link>http://www.jeccr.com/content/27/1/10</link>
			
			 	<dc:creator>Gian Luca Baiocchi, Nazario Portolani, Francesco Bertagna, Federico Gheza, Claudio Pizzocaro, Raffaele Giubbini and Stefano M Giulini</dc:creator>
			
			<dc:source>Journal of Experimental &amp; Clinical Cancer Research 2008, 27:10</dc:source>
			<dc:date>2008-06-10</dc:date>
			<dc:identifier>doi:10.1186/1756-9966-27-10</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Experimental &amp; Clinical Cancer Research</prism:publicationName>
					
			
							
					<prism:issn>1756-9966</prism:issn>
					
			
							
					<prism:volume>27</prism:volume>
					
			
							
					<prism:startingPage>10</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-10</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jeccr.com/content/27/1/9">
            
            <title>Malignant lymphomas (ML) and HIV infection in Tanzania</title>
			<description>Background:
HIV infection is reported to be associated with some malignant lymphomas (ML) so called AIDS-related lymphomas (ARL), with an aggressive behavior and poor prognosis. The ML frequency, pathogenicity, clinical patterns and possible association with AIDS in Tanzania, are not well documented impeding the development of preventive and therapeutic strategies.
Methods:
Sections of 176 archival formalin-fixed paraffin-embedded biopsies of ML patients at Muhimbili National Hospital (MNH)/Muhimbili University of Health and Allied Sciences (MUHAS), Tanzania from 1996&#8211;2001 were stained for hematoxylin and eosin and selected (70) cases for expression of pan-leucocytic (CD45), B-cell (CD20), T-cell (CD3), Hodgkin/RS cell (CD30), histiocyte (CD68) and proliferation (Ki-67) antigen markers. Corresponding clinical records were also evaluated. Available sera from 38 ML patients were screened (ELISA) for HIV antibodies.
Results:
The proportion of ML out of all diagnosed tumors at MNH during the 6 year period was 4.2% (176/4200) comprising 77.84% non-Hodgkin (NHL) including 19.32% Burkitt's (BL) and 22.16% Hodgkin's disease (HD). The ML tumors frequency increased from 0.42% (1997) to 0.70% (2001) and 23.7% of tested sera from these patients were HIV positive. The mean age for all ML was 30, age-range 3&#8211;91 and peak age was 1&#8211;20 years. The male:female ratio was 1.8:1. Supra-diaphragmatic presentation was commonest and histological sub-types were mostly aggressive B-cell lymphomas however, no clear cases of primary effusion lymphoma (PEL) and primary central nervous system lymphoma (PCNSL) were diagnosed.
Conclusion:
Malignant lymphomas apparently, increased significantly among diagnosed tumors at MNH between 1996 and 2001, predominantly among the young, HIV infected and AIDS patients. The frequent aggressive clinical and histological presentation as well as the dominant B-immunophenotype and the HIV serology indicate a pathogenic association with AIDS. Therefore, routine HIV screening of all malignant lymphoma patients at MNH is necessary to enable comprehensive ARL diagnosis and formulation of preventive and therapeutic protocols.</description>
			<link>http://www.jeccr.com/content/27/1/9</link>
			
			 	<dc:creator>Amos R Mwakigonja, Ephata E Kaaya and Edward M Mgaya</dc:creator>
			
			<dc:source>Journal of Experimental &amp; Clinical Cancer Research 2008, 27:9</dc:source>
			<dc:date>2008-06-10</dc:date>
			<dc:identifier>doi:10.1186/1756-9966-27-9</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Experimental &amp; Clinical Cancer Research</prism:publicationName>
					
			
							
					<prism:issn>1756-9966</prism:issn>
					
			
							
					<prism:volume>27</prism:volume>
					
			
							
					<prism:startingPage>9</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-10</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jeccr.com/content/27/1/8">
            
            <title>Surgical treatment and outcome of pulmonary hamartoma: a retrospective study of 20-year experience</title>
			<description>Background:
Controversy still exists in the indication and timing of surgical treatment of pulmonary hamartoma (PH). The objective of this study is to summarize the experience and the outcome of the surgical treatment for pulmonary hamartomas, and to assess the effectiveness and necessity of surgical therapy administered in patients with pulmonary hamatoma as well as clinical and pathological features and long-term follow-up results.
Methods:
This retrospective report has reviewed a 20-years clinical history of surgical treatment for 39 patients with PH from 1985 to 2006. These thirty-nine patients underwent 40 operations as follows: wedge resection (23), enucleation (10), segmentectomy (3), lobectomy (3), and pneumonectomy (1).
Results:
The PH occurred most frequently (78.1%) in the patients aged 40 to 60 years and the sex ratio (male/female) was 2.25/1 in our series. No postoperative death was encountered. One patient with pleural effusion was cured after thoracentesis. All of these 39 patients were proved with pathologic diagnosis of PH and the popcorn calcification was found in 6 cases before operation. In 38 cases having the mean follow-up of 7.3 years, a patient was operated thrice for regional recurrence.
Conclusion:
Fast frozen section in operation is critical for acquire accurate pathological diagnosis. Due to potential trend of recurrence or malignance, patients with hamartoma should be submitted to a complete evaluation and a regular follow-up.</description>
			<link>http://www.jeccr.com/content/27/1/8</link>
			
			 	<dc:creator>Wei Guo, Yun-Ping Zhao, Yao-Guang Jiang, Ru-Wen Wang and Zheng Ma</dc:creator>
			
			<dc:source>Journal of Experimental &amp; Clinical Cancer Research 2008, 27:8</dc:source>
			<dc:date>2008-05-31</dc:date>
			<dc:identifier>doi:10.1186/1756-9966-27-8</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Experimental &amp; Clinical Cancer Research</prism:publicationName>
					
			
							
					<prism:issn>1756-9966</prism:issn>
					
			
							
					<prism:volume>27</prism:volume>
					
			
							
					<prism:startingPage>8</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-31</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jeccr.com/content/27/1/7">
            
            <title>Detection of sentinel and non-sentinel lymph node micrometastases by complete serial sectioning and immunohistochemical analysis for gastric cancer</title>
			<description>Background:
We investigated the presence and distribution of the sentinel and the non-sentinel node micrometastases using complete serial sectioning and immunohistochemical staining (IHC), to inspect whether lymph node micrometastases spread to the sentinel lymph nodes first.
Methods:
A total of 35 patients, who underwent gastrectomy with a sentinel lymph node biopsy for gastric cancer, were enrolled in this study. Total of 1028 lymph nodes of 35 patients having gastric cancer without metastasis of lymph node by permanent section with hematoxylin and eosin staining (H&amp;E) were selected. There were 252 sentinel nodes and the other 776 were non-sentinel nodes. All nodes were sectioned serially and stained alternately with H&amp;E and IHC. Lymph node micrometastases was defined as proving to be positive first either the IHC or the complete serial sectioning.
Results:
Micrometastases were detected in 4 (11%) of the 35 patients, 6 (0.58%) of 1028 nodes. Of these 4 patients, 3 had micrometastases exclusively in sentinel nodes, and the other had micrometastasis in both sentinel and non-sentinel nodes. There was no patient who had the micrometasitases only in non-sentinel nodes.
Conclusion:
These results support the concept that lymph node micrometastasis of gastric cancer spreads first to sentinel nodes.</description>
			<link>http://www.jeccr.com/content/27/1/7</link>
			
			 	<dc:creator>Kaname Ishii, Shinichi Kinami, Kenichiro Funaki, Hideto Fujita, Itasu Ninomiya, Sachio Fushida, Takashi Fujimura, Genichi Nishimura and Masato Kayahara</dc:creator>
			
			<dc:source>Journal of Experimental &amp; Clinical Cancer Research 2008, 27:7</dc:source>
			<dc:date>2008-05-30</dc:date>
			<dc:identifier>doi:10.1186/1756-9966-27-7</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Experimental &amp; Clinical Cancer Research</prism:publicationName>
					
			
							
					<prism:issn>1756-9966</prism:issn>
					
			
							
					<prism:volume>27</prism:volume>
					
			
							
					<prism:startingPage>7</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jeccr.com/content/27/1/6">
            
            <title>Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations</title>
			<description>Malignant Mesothelioma is an uncommon and very aggressive tumor that accounts for 1% of all the deaths secondary to malignancy in humans. Interestingly, this neoplasm has been occasionally described in companion animals as well. Aim of this study was the preclinical evaluation of the combination of piroxicam with platinum-based intracavitary chemotherapy in pets. Three companion animals have been treated in a three years period with this combination. Diagnosis was obtained by ultrasonographic exam of the body cavities that evidenced thickening of the mesothelium. A surgical biopsy further substantiated the diagnosis. After drainage of the malignant effusion from the affected cavity, the patients received four cycles of intracavitary CDDP at the dose of 50 mg/m2 every three weeks if dogs or four cycles of intracavitary carboplatin at the dose of 180 mg/m2 (every 3 weeks) if cats, coupled with daily administration of piroxicam at the dose of 0.3 mg/kg. The therapy was able to arrest the effusion in all patients for variable remission times: one dog is still in remission after 3 years, one dog died of progressive disease after 8 months and one cat died due to progressive neoplastic growth after six months, when the patient developed a mesothelial cuirass. The combination showed remarkable efficacy at controlling the malignant effusion secondary to MM in our patients and warrants further investigations.</description>
			<link>http://www.jeccr.com/content/27/1/6</link>
			
			 	<dc:creator>Enrico P Spugnini, Stefania Crispi, Alessandra Scarabello, Giovanni Caruso, Gennaro Citro and Alfonso Baldi</dc:creator>
			
			<dc:source>Journal of Experimental &amp; Clinical Cancer Research 2008, 27:6</dc:source>
			<dc:date>2008-05-19</dc:date>
			<dc:identifier>doi:10.1186/1756-9966-27-6</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Experimental &amp; Clinical Cancer Research</prism:publicationName>
					
			
							
					<prism:issn>1756-9966</prism:issn>
					
			
							
					<prism:volume>27</prism:volume>
					
			
							
					<prism:startingPage>6</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-19</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
